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uMMARY Lymphokine activated killer cells (LAT< cells) or interIeukin 2 (IL-
2100ti, at, d killer^ colts w"re ladu. "d by re. ,in binant IL-2 (TCP-3) f. " dini. al
adoptive Immunotherapy of malignant diseases. After Incubation of peripheral
blood lymphocytes (PBL) with IL-2 and normal human plasma for I-2 \VCeks LAK
cells werc obtaincd that showed a maximum cytotoxicity against target cells, and
did not need a toxic dose of IL-2 to enhance or maintain their cytotoxicity. Both
autologous and allogencic LAK cells were Lised in five clinical cases without any
jinmunc side effects, and were effectivc in thrce cases.
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INTRODUCTION
Tmmunothcrapy of malignant diseases is now
being studied IntensiveIy, liecausc theoretical-
Iy it should be effective for specific treatment
of tumors. T'he cliscovery of cytokines pro-
ducecl by immune response cells has con-
tributed not only to analysis of the functional
relationships of cells but also to the clinical
treatment of various malignancies
InterICUkin 2 (IL-2), a reprcsentative cyto-
kinc, which causes proliferation and activa-
tion of T lymphocytes, was first named T cell
g". wth fartor (TCGF) (M, "gan at a1. , 1976).
Rosenberg et al. treated patients with in a-
jignant diseases, especially cutaneous and
pulmonary metastases, with activated lympho-
cytes expanded by IL-2, which they called
LAl< colts (lymph. king". tivat"d killer colts)
Key \\'ords : Adoptive jinmunotherapy, Interleu-
kin 2, Lymphokine activated 1</11er cells
(Rus'riberg, 1984; Rus'rib""g at "I. , 1985).
In their in vivo experiments, they used LAK
cclls Induced from splenocytes in an incuba-
tion period of a few days. They found that
injection of IL-2 at 8-hour intervals was
necessai'y to maintain the activity of LAK
cells, and the^ obtained effective results when
IL-2 and LAl< cells were injected simtil-
tone. us Iy (Rus'riberg, 1985). instd on thus"
experimental results, in clinical studies Rosen-
herg at al. used high doses of IL-2 and LAK
cells induced from patients' peripheral blood
lymph, cyt, ^ (PBL) by th. it in. "bad, n with
IL-2 for a few days. This treatment was
therapeutically effective, but patients treated
with very high doses of IL-2 suffered from
toxic side effects, such as the capillary perme-
ability Ieal< syndrome, resulting in marked
fluid retention and body weight gain and
psycological disorders (Rosenberg at al. ,
29
1986).
Thus, it Is very Important to produce LAK
cells with higher cytotoxic activity that do
not require such high, toxic doses of IL-2.
Another problem in adoptive
therapy with LAK cells and IL-2 is that so-
called blocking factors (Hellstr6m at a1. , 1974;
Kimoto at a1. , 1987a, Kimoto et a1. , 1987b)
in the plasma of cancer patients may inhibit
the cytocidal effect of LAT< cells.
In the absence of ITUman plasma, normal
PBL activated by IL-2 show high cytotoxicity
as effector cells in vitro. Normal plasma does
not block the cytotoxicity of IL-2-activated
PBL ^ignifi. antly (Kim. t. , 1986), but th.
plasma of patients' decreases the cytotoxicity
of these normal effector cells. \\Ihen pa-
tients' autologous PBL and plasma are used
simultaneously in the cytotoxic assay, the cyto-
toxicity of the IL-2-activated PBL is de-
or, "^. d ^ignifi. antly (Kim, t. , 1986), and th.
continuous presence of IL-2 is required to
maintain the cytotoxicity of IL-2-activated
PBL in the presence of patients' plasma (Ki-
inot0,1986).
Therefore, \\, e tried to obtain LAK cells
that maintained maximum cytotoxidty even
in the presence of patients' plasma. \\!e have
reported the change in cytotoxicity of IL-2-
activated PBL during incubation with IL-2
and human normal plasma (Kimoto at al. ,
1987c). Usually LAK cells seemed to be in-
duced after incubation for a few days (Grimm
at a1. , 1982, Doyle et a1. , 1985). However,
the cytotoxicity of the autologous LAK cells
induced by our method reached a maximum
after incubation for two weeks, and this cyto-
toxicity was maintained for further two weeks
in the presence of IL-2 (Kimoto at a1. , 1987c).
The cytotoxicity of allogeneic LAK cells in-
duced in cultures of mixed PBL obtained
from ten donors, reached a maximum after
incubation for seven to ten days, and was
maintained for another one week even at a
low effector to target (E: T) ratio and in the
presence of patients' plasma (Kimoto at al. ,
1987d).
Immuno-
Therefore, considering the possible E: T
ratio in the body of patients, the cells trans-
furred for adoptive Immunotherapy should be
ciiltured for two weeks in the case of auto-
logous LAK cells and for seven to ten days
in the case of mixed cultures of allogeneic
LAT< cells.
Addition of IL-2 (TCP-3) at , high c. n-
centration of 0.5 Ujml could enhance the
cytotoxicity of LAK cells in vitro (Kimoto at
a1. , 1987b), suggesting that IL-2 maintained
or increased the cytotoxicity of LAl< cells in
vivo in patients when injected simultaneously
with the LAl< cells. In in vitro experiments
we found that LAT< activity reached a maxi-
mum at concentrations of 0.1-02 Ulml of IL-
2, suggesting that this serum level of IL-2
was required to maintain the LAK activity and
that a higher concentration was not necessary
(Kimoto at al. , in preparation). Pharmaco-
kin, ti. studi, ^ (T"gushi, 1986) ^h, wad that
after intravenous injection of 2000 U of IL-2,
the concentration IL-2 reached a maximum of
0459 Ulml in the patient's serum, the half
life of IL-2 was 0.41 h and the AUC (area
under curve) was 0,499 U. hrjml. Thus the
serum level of IL~2 decreased rapidly. On
the other hand, after intramuscular injection
of 1000 U of IL-2 the maximum concentra-
tion was 0.060 Ulml, the half life was 1.26 h
and the AUC was 0277 U. hrlml. Thus the
serum level of IL-2 decreased gradually and
IL-2 could still be detected 8 h after its
intramuscular injection. Consistent with
these pharmacokinetic studies, we found in
in vitro experiments that for enhancement of
there was no difference be-LAK activity
tween the effects of intravenous Infusion of
IL-2 for one hour and its intramuscular in-
jection (Kimoto at al. , in preparation).
In this paper we report successful clinical
trials of adoptive jinmunotherapy with LAK
cells induced by our method given with non-
toxic doses of IL-2. The safety of adoptive
transfer of normal allogeneic LAK cells is
also discussed.
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A1ATERIALS AND A1^ETHODS
I. 1/1/'71ei, Alit 2
Recombinant 11Tterleukin 2 (TCP-3) \\."s kindl\.
supplicd by Talked a Chemical Industries, Ltd
One unit of TGP-3 was defined as the amount of
IL-2 present in I in I of supernatant after incLibation
of 5 XIO"jinl of normal I'BL in RFi\{116+0 contain-
ing 1011, fetal calf serLim, 40 jigjml of Con A and
15 rigjml of 12-0-tetradccanoylphorb01-13 -acetate
for 721tours at 37 C
2. I'lle, Iero, is
In two cases we Injected interferons (IFNs)
several times simultaneously with adoptive Immuno-
tlTerapy. Recombinant IFN-n, \\. ith a specific
activity of 2-+ XIO' IUjmg protein and more than
9516 purity, and recombinant IFN-I \\, ith a specific
activity of more than 1.64xlO' Ujmg protein and a
purity of more tltan 95'. 1, were supplied by Takedn
Chemical Industries, Ltd. Recombinant IFN-,
witl\ a specific activity of 5 XIO' Ujmg protein and
purity of more than 991h \\. as SLIPplied by 1<yowa
Haitito Co. , Ltd
were incubated with LAl< cells for 2 da\, s in mediunt
with or \\, ithout IL-2 and plasma of the patient in a
flat-bottomed Inicrotest plate. The hepariit (5 Uj
in I) present in the plasma as an anticoagulant did not
Influence the cytotoxic assays. After incubation,
the number of live target cells in the microtest
plates \\, as counted by the neutral red dye-uptake
method, and the sur\Ival rate of target cells \\. as
calculated relati\ e to tlTe control, in \\, hich the target
cells \\, ere incubated \\. ithout IL~2 or LAl< cells
The optical density (OD, ,,) was proportional to the
number of live target cells. Almost all LAl< cells
were removed by washing \\. itit phosphate-buffered
saline before addition of neutral red and they, ITad
little affect on the count of target cells. The per-
centage survival of target cells and tlTe inhibition
rate or cytotoxicity \\, ere calculated as follo^. s : 91
survival=(OD, ,, of the experiment 100, ,, of the
control) x 100 % inhibition or c\. to toxicit} =100-
111 survival
3. filth, cii'o11 of LAK tc//s
PBL separatcd from the blood of patients or
normal donors were incubated \\, it I\ recombinant
IL-2 (TGP-3) to generate colts capable of killing
tumor cells. PBL \\. ere isolated from 2000 to
4000 in I of blood by Ieukapheresis Lising CS-3000
(Fen\\. al) and were purified by Ficoll-Paque gradient
sedimentation (Biiyum, 1968). TITen, titey, were
incubated at an initial concentration of 2 xiO"
c"11.1ml in RPM116+0 cont"ining 3 Ujml of IL-2,
10-1316 normal human plasma of the same blood
type as titat of the patient and 5 U!in I of he pann as
anticoagtilant. Judging from our pre\, lotis
experiments, IL-2 sitoLild be present continuousl},
in the mediunt and 3 Ujml \\. as sufficient for this
inclibation. The LAl< cells \\, ere induced in a cell
factory, witlt ten chambers (Nunc) to save time, and
medium containing 3 Ulml of IL-2 \\."s added every
three or four day's. Autologous cells were incubated
for two \\, eeks and allogeneic cells \\, erc incubated for
seven to ten days at 37 C tinder an atmosphere of
5% CO2 in air
an
5. Prepnrnti'oil of LAK cells for ridop!,'"e tm, isle, '
After incubation in the cell factories, the LAK
cells were collected and washed three times with
phosphate-buffered saline. Titcn I-10 x 10' LAK
cclls were suspended in 100 inI of saline containing
2000 U of IL-2. The suspension \\, as injected
Intravenously over a five minLite purlod Lung a
blood infLision set witl, me sit to reino\, e debris.
The cells \\, ere injected I-3 times a \\. cck followed by
Intravenous or intramuscular injection of 1000 U
or 2000 U of IL-2 the next dav
4. Cytotox, 'c nssny 171 antro
Adhesive target cells S\\'1/16, a human colon
adenocarcinoma cell line (Leibovitz at a1. , 1976).
RESULTS
I. Cytotoritity of LAK cells Inst bqfore adop-
1171e Ir", lifer
Fig. I shows the cytotoxicity of autologous
and allogeneic LAK cells prepared for adop-
tive transfer to patients. Autologous LAK
cells showed about 90 to 959', cytotoxicity after
two \\, eeks' incubation even at an E : T ratio
of I : I and in the presence of patient's own
plasma, and the cell via billty was more than
80y, . Th. LAT< colts of bl. .d typ" B. Rh(+)
and ORh(+) showed cytotoxicity after seven
to ten days' incubation, as shown in Fig. I.
Though some live target cells remained at an
E: T ratio I: I, almost all target cells \\, ere kil-






















Cytotoxicity of~LAK cultured in cell factory
.
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Cytotoxicity of autologous and allogeneic LAK cells cultured in a cell factory. The cytotoxicFIGURE I
assay against Swill6 \\, as carried out just before adopti\, e transfer. top : assay in RPM11640 containing
10% FCS. bottom : assay, in RPM11640 containing 696 FCS and 20% patients' plasma as a blocking factor
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led when the E: T ratio was raised to 3 : I or
10: I. Additional IL-2 at a concentration of
0.5 Ulml enhanced the cytotoxicity.
After incubation, the number of LAK cells
increased to one to five times the number of
PEL be forc incubation, but 2- to 3-fold proli-
feration was usual and the viability of the LAK
cells was 80-100%.
2. Case yepo, .ts rr"of c/!}izeal ayects
Five cases with metastases of the various
malignancies shown in Table I received adop-
tive jinmunotherapy with LAK cells gen-
Grated by the culture method described above.
3 :I 10 :I


















In case I, 8.6 x 107 LAK cells induced from
PBL in the patient's pleural effusion were
injected into the pleural cavity with IL-2.
The LAK cells were left in the pleural cavity
for several days, and then continuous drain-
carried out for one week. Tumorage was
cells had disappeared from the pleural Gnu-
started. Thebefore drainage
pleural effusion completely disappeared in
five months \\, hen the patient died of he patic
metastasis.
Case 2 had five pulmonary metastases of
adenocarcinoma and received I-mammary
10 x 10' of autologous LAT< cells, 2000 U of
BIKEN JOURNAL \101.30 No. 21987
SIon was












































IL-2 and interferon mixture (,", 3 XIO" IU; p,
3xlO"IU; r, 2xlO"IU). One of the metas-
tases of 9 mm diameter completely disap-
peared and the other two decreased from
10x9 mm to 9x8 mm and from 16x13 mm
to 14x13 mm, as shown by chest roento-
genograms. After 14 transfers of autologous
LAT< cells, allogeneic LAT< cells of normal
donors were transferred with IL-2 once a
week because slight pancytopnea developed
and sufficient PBL could not be obtained by
Ieukapheresis. These five metastatic lesions,
including the one that disappeared, showed
slow regrowth in spite of the weekly adoptive
transfer. Then combination chemotherapy
and adoptive jinmunotherapy were applied,
resulting in effective therapy that is now in
p". gre^* (Fig. 2).
In case 3, a squamous cell caranoma of the
GPipharynx was resented and one year later
giant metastatic lesions were found in both
lungs, the liver and the abdominal wall.


























, 9 X 1010
Iy+
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bodies against EB virus. Then allogeneic
LAK cells induced from PBL of normal
donors were transferred two or three times a
work with rec. in binant IFN-," (3 x 10" IU).
Of the multiple pulmonary metastases one of
30 mm diameter and one of 20 x 10 mm re-
gressed completely, a left hilar metastasis be-
came smaller, one hepatic metastasis disap-
peared under ultrasonic examination, and a
tumor on the abdominal wall became smaller,
but no change was observed in the other
The patient died abruptly ofmetastases.
massive hemorrhage from a hilar metastasis
of the right lung on \\, hiclT this therapy had
not apparently been effective (Fig. 3).
Case 4 It ad one pulmonary metastasis of a
rhabdomyosarcoma that gre\\, rapidly in a few
months. The patient received allogeneic nor-
mai LAK cells systemically two or three
times a week. During this therapy for five
months growth of the tumor stopped, but the
tumor did not become smaller. Then the
tumor \\, as resected, and after the operation,
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FIGURE 2. Clinical course of a patient (Case 2) who had pulmonary. metastatic lesions of a mammary
adenocarcinoma. The patient \\, as treated by adoptive jinmunotherapy alone in 1986, and in combination





adoptive Immunotherapy with allogeneic LAK
cells and 2000 U of IL-2 has been continued
to prevent growth of the remaining micro-
metastases.
Case 5 has a large metastasis of a colon
adenocarcinoma in the liver. LAT< cells and
IL-2 have been injected into the he patic artery
and therapy is still in progress.
3. 8111e ofecis
Fever was usually experienced a few hours
after eacl\ systemic injection of LAK cells and
IL-2, which were given concomitantly with
in domethacin. Sometimes patients experi-
enced nausea and general fatigue, but without
the necessity of use of therapeutic drugs.







the period of Ieukapheresis, and disappeared
when normal allogeneic LAT< cells were used.
Following rapid injection of LAT< cells
intravenously, no side effects such as pul-
monary embolism or cardiac infarction were
experienced. Roentogenograms of the chest
taken directly after rapid injection of LAK
cells showed no significant differences from
those taken before the injection. No infoc-
tious diseases or sepsis were experienced dur-
Ing this therapy.
34 BIKEN JOURNAL V01.30 No. 2 1987
4. Co, ,laini"nil'0"
Of more than one hundred cultures, only
two were contaminated by Candida species,
and these were discarded. There were no
accidents in patients and no bacteria or my-
TZA, 27M.










FIGuni; 3. Clinical course of a patient (Case 3) \\'ith giant metastatic squamous cell carcinoma in both lungs
Some metastases in the left lung diminished, but nTassi\ e Itemorrhage occurred in the right lung
Q '?4 '8,
RIP, ;86
coplasma \\, ere detected in culttirc media
5 . G, '4/1 DCIS"s nost ledct, o11
In cases 2, 3 and 4 allogeneic LAT< cells
were injected frequently. Only ABO- blood
types were matched. No side effect involv-
ing an ariaphylactic reaction or toxic Immune
disease \\, as experienced clinicalIy. However,
there was a higlT possibility of occurrence of
the graft versus host (GVH) reaction. Lab-
oratory data revealed no significant change in
the amount of immunoglobulins. Before
each injection of allogeneic LAT< cells, a
small volume of LAT< cells with infusion saline
containing IL-2 was tested Intracutaneously,
but no rapid reactions were detected









Rosenberg et al. in USA were pioneers in
adoptive jinmunotherapy with LAT< cells.
In their clinical trial, they used autologous
LAl< cells obtained by frequent Ieukapheresis
followed by a few days' incubation (Rosen-
herg, 1984; Rosenberg, 1985; Rosenberg at
a1. , 1985). Althougl\ no antitumor effect of
IL-2 alone was detected (Lotze at a1. , 1984),
they injected an extremely large amount of
IL-2 to maintain the LAT< activity of the cells
Iruccted Into patients. This therapy was
based on the effectiveness of autologous LAK
cells, which might possess autologous tumor-
antigen specificity upon autologous tumor
cells (Lotze at a1. , 1981; Grimm et a1. , 1982;
Yank^ at a1. , 1982) and the effectiveness of
adoptive transfer of LAT< cells into mice
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bearing experimentalIy established pulmo-
nary and he patic metastases (A1azumder and
Rosenberg, 1984; Lafreniere et a1. , 1985)
In some cases they obtained good results, such
as complete regression of skin metastases of
a malignant melanoma and partial regression
of pulmonary metastases of a colorectal can-
CGr, renal-cell carcinoma, melanoma and pri-
mary lung cancer (Rosenberg et a1. , 1985)
I\loreover, local injection of LAT< cells re-
SUIted in complete regression of skin meta-
stases of a malignant melanoma and partial
regression of a soft part metastatic mammary
carcinoma (Adler et a1. , 1984). However, the
side effects of high doses of IL-2 were ex-
tremely severe, as described above.
On the other hand, we found that the LAK
cells induced after one to two weeks' incuba-
tion by our method using IL-2 and normal
human plasma possessed cyto-
toxicity even at a low E: T ratio under the in-
Huence of the patients' plasma. The results
suggested the importance of the incubation
period. Moreover IL-2 injected at the fre-
quency and the doses described in Table I for
maintenance of the LAT< activity in vivo in
the patient did not cause any toxic side ef-
fects.
Neither autologous nor allogeneic LAK
cells caused any side effects, such as inforc-
tion or pulmonary embolism. However,
when allogeneic LAT< cells are used for adop-
tive transfer, there is a possibility that a toxic
immune response against allogeneic antigens
involving HLA could occur in these patients
after frequent injection of LAT< cells from
other persons, Theoretically HLA types
should be matched, and 1<0hler at al. used
LAT< cells obtained from identical or haplo-
toxic side ef-identical donors without any
font^ (K. him at a1. , 1985). Additi. inI al-
logeneic LAl< cells should be transferred
very cautiously, even when there Is no signi-
ficant immune response.
it is sometimes very difficult to obtain
sufficient PBL from a patient, and it Is very
dangerous to culture bacteria- or virus-In-
fected PBL for generating LAT< cells. For
such patients, allogeneic LAT< cells from
normal donors could be available. \\!ith
regard to the safety of transfer of allogeneic
cells, it is noteworthy that large amounts
of fresh blood can be transferred safely after
massive hemorrhage and that no detectable
GVH usually occurs.
Moreover, mixed culture of normal al-
logeneic PBL from more than one donor ap-
pears to induce LAT< cells capable of Iysing
other PBL in the culture while reacting with
alloantigens of other individuals. The ac-
of these LAT< cells increased earliertivity
than the autologous LAK activity even though
the number of LAK cells was smaller due to
this interaction
In three patients who received intravenous
adoptive transfer of LAK cells, some pul-
monary metastases regressed completely or
partially, but other pulmonary metastases,
even in the same patient, did not show any
marked change. LAT< activity is considered
to be nonspecific (Rosenberg, 1985 ; Rayner
et a1. , 1985), but there appear to be differences
in sensitivity of malignant cells to LAK cells.
Moreover, there are probably some other
or thedifferences such as in angiogenesis
distribution of LAK cells
In two cases we used IFN(s) \\, hich could
support the activity of LAT< cells. IFN-cr
can kill EB virus and is effective on squamous
cell carcinoma of the epipharynx and an IFN-
mixture showed a much stronger direct effect
on target cells in vitro than one IFN alone
(Kimoto at a1. , 1986), and also enhanced the
cytotoxic activity of IL-2-activated killer cells
(Kimot0, 1986). However, we usually could
not obtain complete regression of pulmonary
metastases using IFN(s) alone. Tile elfec-
tiveness in cases 2 and 3 could, therefore, be
the effect of a combination of adoptive Im-
inunotherapy and IFN(s)
In the future more Intensive adoptive jin-
inunotherapy will be required, if possible us-
ing tumor-specific cytotoxic effector cells.
In adjuvant therapy LAK cells should be
maximum
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transferred to patients who have micrometa-
static lesions and a high possibility of recur-
Probably, combination therapy, \\, Ith
biological rcsponse modifiers or cytokines
Tence.
REFERENCES
Adjer, A. , Stein, I. A. , 1<edar, E. , N"dor, D. , \\'CISs,
D. \V. 198+. Intralesional injection of inter-
IeLikin-2-expanded autologous Ivmphocytes in
melanoma and breast cancer patients: A pilot
study. I. Biol. Response MDd. 3 : +91-500
B6yum, A. 1968. Isolation of leukocytes from
htiman blood. A, letltvl cellulose, dextran and
ScandF1coll as erythrocyte-aggregating agents
I. Clin. Lab. Inv. st. Supp1.21 : 31-50
Doyle, A, I. V. , Lee, I\I. T. , Fong, S. 1985. Coin-
parison of the biological activities of ITUman
recombinant InterICUkin-21.5 and nati\'c Inter-
landn-2. I. Biol. Respon*c A{od. +: 96-109
Grimm, E. A . A, inzumdcr, A. , Zhang, I{. Z. ,
Rosenberg, S. A. 1982. Lymphol<inc-anti\, ated
1<illcr cell pheitomcnon. Lysis of it at ural 1</11er-
resistant freslt solid tumor cells by inturlcul<in
2-acti\. ated autologous human peripheral blood
lymph, cytes. I. Exp. Med. 155: 1833-1841
Hellstr6m, 1<. E. , I-lullstr6m. I. 1974. Lympho-
cyte-mediated cytotoxicity and blocking serum
Adv. jinmLin01.18activity. to tumor antigens
209-277
Kimoto, Y. 1986. In \. itTo cnltanccment of cyto-
toxicity of hLiman peripheral blood lymphocytes
with recombinant IL-2 and interferon ntixtLire
(, I+,; +I ) against ITUman colon carcinoma cell line
S\\, 1116. JPn. I. Can. ", Chemotl, e". 13: 3+19-
3426
Kimoto, Y. , Taguchi, T. 1987n. Inhibition of
anti-tumor errcct of mouse monoclonal antibodv
17-IA by hLiman plasma. JPn. I. Cancer
Chemother. 14: 459-466
Kimoto, Y. , Tnnji, Y. , Onkasa, H. , Usugane, A1. ,
Fujita, IVl. , TagLiclti, T. 1986. Combined effect
of interferons it, 13 and I on tumor growth in
JPn. I. Cancer Chemothcr. 13 : 302-307vitro
Kimoto, Y. , Tanji, Y. , Taguchi, T. 1987b. Blocking
factors in human blood \\, it ich inhibit cytotoxicity
of lymphocytes against malignant cells. JPn. I
Cancer Chemotlter. 14: 453,158.
Kimoto, Y. , Tanji, Y. , Tanal{a, T. , Taguchi, T
1987c. Adoptive jinmunotherapy of malignant
better resultssuch as IFNs \\, ould give
Further analysis of the blocking factor(s) and
its removal also seem important
diseases witl, LAl< cells. JPn. I. Cancer Chento-
ther. 14: 687-692
Kimoto, Y. , Tanji, Y. , 'Fanaka, T. , Taguchi, T
1987d. Adoptive irumunotheTapy of malignant
diseases LISing normal allogcneic LAl< cells. JPn
I. Cancer Chemothe, . 14: 1884-1889
1<iruoto, Y. , Tanji, Y. , Tnnaka, T. , Taguchi, T
Toxic doses of IL-2 are not necessar\, to ntain-
tain cytotoxicity of LAl< cells indLiced by long
culture. JPn. I. Cancer Chemothcr. iiT press
Kohler, P. C. , Hank, I. A. , Ext"n, R. , MinimfT,
D. Z. , \Vilson, D. G. , Sondel, P. AJI. 1985
Clinical response of a patient with diffLise ITistiocy-
tic lymphoma to adoptive chemoimmunothcrap\.
using cycloplTosphamide and alloactivated It tiploi-
dentical lymphocytes. A case report and phase
I trial. Cancer 55: 552-560
Lnfreniere, R. , Rosenberg, S. A. 1985. Successful
Iminunothcrapy of in urine experimental I. epatic
metastascs with lymphol<ine-"ctiv"ted killer cells
and recombinant interIeukin 2. Cancer Res. 45 :
3735-3741
Leibovitz, A. , Sting on, I. C. , NICCombs, W. B. .
A{CCDy, C. E. . IViazur, 1<. C. , Mahry, N. D. 1976
Classificatioi, of ITUman colorectal tideitocarcinoma
cell lines. Cancer Res. 36 : 4562-4569
Lotze, M. T. , Grimm, E. A. , AllazLimder, A. ,
Strausscr, I. L. , Rosenberg, S. A. 1981. Lysis
of freslT and cultLircd autologous tLimor by ITUman
lymphocytes CLIltured in T-cell growtl\ factoi'
Cancer Res. 41 : 4420-4425.
Lotze, M. T. , Robb, R. I. , Sharrow, S. 0. , Frantt,
L. \\'. Rosenberg, S. A. 1984. Systemic ad-
ministration of interIeukin-2 in ITUmans. I. Biol
Response MDd. 3 : 475-482
A, Iazumder, A. , Rosenberg, S. A. 1984. SLiccessfLil
jinmunotlterapy of natural killer-resistant estnb~
lishcd pulmonary melanoma metastases by the
intravenous adoptive transfer of syngeneic Iym-
phocytes activated in \, It To b}, litterIeukin 2. I
Exp. I\led. 159: 495-507.
NIOrgan, D. A. , Ruscetti, F. \\,., Gallo, R. 1976
Selective in \. it To growth of T lymphocytes from
KIMOTo, Y. Adopt, be 1/1/'11, ,, 10the, ripy 2011/1 LAK tells 37
normal bone marrows. Science 192: 1007-1008
Rayner, A. A. , Grimm, E. A. , Lotze, lv'I. T. , Chu,
E. \\7. , Rosenberg, S. A. 1985. Lymphokine-
activated 1</11er (LAK) cells: Analysis of factors
relevant to the jinmunotherapy of human cancer
Cancer 55: 1327-1333
Rosenberg, S. A. 1984. Tmmunotherapy of cancer
by SI, stemic administration of lymphoid cells plus
interIeukin 2. I. Biol. Response MDd. 3 : 501-511
Rosenberg, S. A. 1985. Lymphokine-activated kil-
Ier cells : a new approach to jinmunotherapy of
I. Natl. Cancer Inst. 75 : 595-603.
Rosenberg, S. A. , Lotze, A{. T. , Muul, L. M. ,
Leitman, S. , Chang, A. E. , Ettinghausen, S. E. ,
Anatory, Y. L. , Skibber, I. M. , Shiloni, E. , \letto,
I. T. , Seipp, C. A. , Simpson, C. , Reichert, C. M
cancer
1985. Observation of the systemic administra-
tion of autologous lymphokine-activated killer
cells and recombinant interIeukin-2 to patients
witlT metastatic cancer. N. Engl. I. iVled. 313 :
1485-1492
Rosenbcrg, S. A. , Spiess, P. , Lafreniere, R. 1986
A new approach to the adopti\, e jinmunotherapy
of cancer with tumor-inintrating lymphocytes
Science 233: 1318-1321
Taguchi, T. 1986. Interletikin-2 and cancer treat-
JPn. I. CanCG" Chemother. 13 : I-10merit
Vanky, F. , GOTsky, T. , COTSky, Y. , Masucci, A{.,
Klein, E. 1982. Lysis of tumor biopsy, cells by
autologous T lymphocyte activated in mixed
cultures and propagated with T cell growth factor
I. Exp. Med. 155: 8345
38 BIKEN JOURNAL V01.30 No. 21987
